Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Amazon Explores AI Content Marketplace With Media Publishers 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Vyome Partners with a Large, Global Specialty Pharmaceutical Company to Market its Dandruff Products
NEW DELHI, India, Feb. 26, 2018 -- Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announces the licensing and supply if its novel products for the treatment of mild to moderate scalp seborrheic dermatitis, commonly known as dandruff, to its exclusive licensing and marketing partner in India.
Vyome developed VB-001, an anti-dandruff lotion product, and VB-3222, an anti-dandruff shampoo using the company’s patented Molecular Replacement Therapeutics (MRT™) platform technology. Vyome has clinically tested these products with the demonstration of their clinical efficacy. Through its partnership with a global and large specialty pharmaceutical company, these products will be available through prescription marketing channel and chemists in India. Vyome retains the right to license and market these products in the rest of the world.
"Vyome is committed to developing innovative antimicrobial dermatological products to provide new treatment options for clinicians and patients,” said Venkateswarlu Nelabhotla (N. Venkat), co-founder and chief executive officer of Vyome Biosciences. “Dandruff affects approximately 50 percent of the world’s population including approximately 200 million patients in India. By partnering with a large specialty pharmaceutical company which is one of global leaders in dermatology, we will make our first two products available to patients with dandruff, for whom current therapeutic options are limited and often less effective.”
Vyome’s Molecular Replacement Therapeutics (MRTTM) are inspired by functional genomics to enhance the efficacy of antifungal agents. Leveraging its innovative antimicrobial technology platforms, Vyome is developing other novel products including VB 1953, a topical product candidate for moderate to severe acne, currently being initiated for Phase 2b clinical trials in the United States.
About VB-001
VB-001 is a clinically tested scalp care leave-on product designed for the treatment of mild seborrheic dermatitis, or dandruff. VB-001 uses Vyome’s patented Molecular Replacement Therapeutics (MRTTM) platform to outperform current gold standards in treatments of skin fungal infections, providing a potential solution for individuals with dandruff.
About VB-3222
VB-3222 is a clinically tested anti-dandruff wash-off shampoo designed for the treatment of dandruff. Developed using Vyome’s MRTTM platform, VB-3222 is clinically proven to reduce scalp flaking and itching.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage bio-pharmaceutical company, which has novel platform technologies and a deep pipeline of novel drugs for antibiotic resistant acne, and other opportunistic skin pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment candidate for moderate and severe acne, has been clinically tested in Phase 1 in the United States and in a proof of concept efficacy study with successful outcomes, and is currently being studied in a Phase 2b study in the United States. Vyome has a deep pipeline of preclinical chemical entities, which are unique in their ability to overcome the development of resistance, and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on the innovative and patented Molecular Replacement Therapeutics (MRT™) technology platform. Vyome has assembled a world-class team of scientific and business development experts from India and the United States who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at www.vyome.in and @VyomeBio.
Media Contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
(646) 751-4361
[email protected]
